Palsonify: patented from NIH-funded research

Crinetics Pharmaceuticals, Inc. reported 5 patents on this drug to NIH as inventions made with NIH grant money. Crinetics Pharmaceuticals lists them with the FDA as protecting Palsonify.

Patent reported to NIH as grant-funded

Medicare paid, 2024

—

before rebates

Medicare, 2020–2024

Medicaid paid, 2024

—

before rebates

NIH grants behind the patents

$326K

whole-grant totals, not the drug's cost

The public record, link by link

1 · Public money
NIH grant to Crinetics Pharmaceuticals, Inc., $326K in all.
2 · Patent
9896432, 10351547, 10597377, 10875839, 11414397, reported to NIH under R44NS092231.
3 · FDA approval
Approved Sep 25, 2025, held by Crinetics Pharmaceuticals (NDA 219070).
4 · Public pays
Not yet in the Medicare or Medicaid spending files, which run to 2024.

The grants

Totals are everything NIH paid on each grant since 1985. A grant usually funded more than this one invention.

Grant	Research	Years	NIH paid
R44NS092231 NINDS, small-business grant	Small molecule somatostatin agonists for neuropathic pain Crinetics Pharmaceuticals, Inc.	2015	$326K

Grant

Research

Years

NIH paid

R44NS092231

NINDS, small-business grant

Small molecule somatostatin agonists for neuropathic pain

Crinetics Pharmaceuticals, Inc.

2015

$326K

The patents

Patents the FDA lists for this drug that were also reported to NIH as grant-funded inventions.

US 9896432
SOMATASTATIN MODULATORS AND USES THEREOF
Reported by Crinetics Pharmaceuticals, Inc.
FDA-listed expiry Jul 12, 2037
US 10351547
SOMATASTATIN MODULATORS AND USES THEREOF
Reported by Crinetics Pharmaceuticals, Inc.
FDA-listed expiry Jul 12, 2037
US 10597377
SOMATOSTATIN MODULATORS AND USES THEREOF
Reported by Crinetics Pharmaceuticals, Inc.
FDA-listed expiry Jul 12, 2037
US 10875839
SOMATOSTATIN MODULATORS AND USES THEREOF
Reported by Crinetics Pharmaceuticals, Inc.
FDA-listed expiry Jul 12, 2037
US 11414397
SOMATOSTATIN MODULATORS AND USES THEREOF
Reported by Crinetics Pharmaceuticals, Inc.
FDA-listed expiry Jul 12, 2037

Crinetics Pharmaceuticals's side

Drug makers pay for the clinical trials that take a compound from the lab to FDA approval, and they often license the patent from the university and pay royalties on sales. Those terms are not public. The FDA's approval records for Palsonify are linked above, and Crinetics Pharmaceuticals's page shows its other drugs on this list. If Crinetics Pharmaceuticals wants to add its account, we will publish it here.

How this is built. Universities and companies that use NIH grants must report the inventions those grants produce to NIH, under the Bayh-Dole Act. NIH publishes the patent numbers and the grants they were reported under. We match those patents to the patents drug makers list with the FDA for each approved drug (the Orange Book), then add what Medicare Part D, Part B and Medicaid paid for each drug. Only patents still listed with the FDA appear, so drugs whose patents have expired drop out, and biologics, which the Orange Book does not cover, are not here yet.

What the numbers mean. "NIH grants" is everything NIH paid out on the grants a patent was reported under, from 1985 on. A grant usually paid for more than the one invention, so it is not the cost of the drug. Medicare and Medicaid figures are gross spending before the rebates drug makers pay back, which are confidential. Companies also paid for the clinical trials that took these drugs to approval; each drug page links the company's own filings.

Sources: NIH RePORTER patents reported under NIH grants (from iEdison); NIH RePORTER project funding; FDA Orange Book patent and product files; Medicare Part D Spending by Drug; Medicare Part B Spending by Drug; Medicaid Spending by Drug. Updated 2026-11-05.